ストックスクリーナーアプリを入手
3.22
1.53%
-0.05
プレマーケット:
3.23
0.010
+0.31%
前日終値:
$3.27
開ける：
$3.32
24時間の取引高:
308.21K
Relative Volume:
0.89
時価総額：
$130.01M
収益：
-
当期純損益:
$-42.05M
株価収益率:
-1.1418
EPS:
-2.82
ネットキャッシュフロー:
$-35.26M
1週間 パフォーマンス:
-4.45%
1か月 パフォーマンス:
-17.65%
6か月 パフォーマンス:
+19.70%
1年 パフォーマンス:
-0.62%
1日の値動き範囲:
$3.17
$3.338
1週間の範囲:
$3.17
$3.51
52週間の値動き範囲:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.22 | 130.01M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
Protara Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
Protara Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Stocks of Protara Therapeutics Inc (TARA) are poised to climb above their peers - Sete News
It would be worthwhile to take a closer look at Protara Therapeutics Inc (TARA) - uspostnews.com
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Sold by LPL Financial LLC - Defense World
The Potential Rise in the Price of Protara Therapeutics Inc (TARA) following insiders activity - knoxdaily.com
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial - streetwisereports.com
Protara Therapeutics Inc Inc. (TARA) Price Performance: A Technical Analysis Perspective - investchronicle.com
Balance Sheet Breakdown: Protara Therapeutics Inc (TARA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright - Defense World
Protara Therapeutics stock drops following interim trial results By Investing.com - Investing.com Nigeria
Protara Therapeutics stock drops following interim trial results - Investing.com Australia
Protara Therapeutics Inc (NASDAQ: TARA)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstr - GuruFocus
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients - Stock Titan
3 Stocks To Watch For When Tariffs Subside - The Globe and Mail
Mountain Province Diamonds Announces Mailing of Meeting Materials For Annual and Special Meeting of Shareholders to Approve Additional Working Capital Facility - The Globe and Mail
Protara Therapeutics (TARA) to Release Quarterly Earnings on Thursday - Defense World
Protara Therapeutics Inc (TARA) gets rating Initiated from Scotiabank - knoxdaily.com
OTCQX Best 50 Virtual Investor Conference Agenda Announced for April 24th - The Globe and Mail
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times
Protara Therapeutics to Host Conference Call on Phase 2 ADVANCED-2 Trial Data for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
No-Brainer Buy Alert: 1 Artificial Intelligence (AI) Stock With Massive Long-Term Potential - The Globe and Mail
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Philip Morris (PM) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):